Health

STAT+: Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 10/11/2026, 18:51:24 UTC.

Briefings

A former Eli Lilly sales representative sued after alleging she was terminated for reporting that the company was promoting Mounjaro, a diabetes drug, for weight loss before FDA approval. The lawsuit was filed in federal court in Texas, where the representative claimed physicians used the drug for weight loss at a sponsored luncheon, which the suit classifies as off-label marketing. The evidence indicates the drugmaker is not permitted to market its drug for unapproved uses, though the specific date of the lawsuit filing is not provided in the source.

Key points

• Jennifer Mansion, a senior territory manager hired by Eli Lilly in Dallas four years prior, filed a lawsuit alleging termination for reporting off-label promotion of Mounjaro.
• The suit claims physicians promoted Mounjaro as a weight loss option at a sponsored luncheon, which the representative argues constitutes off-label marketing.

Context

Mounjaro is a diabetes drug used to treat type 2 diabetes, and the lawsuit involves allegations of off-label promotion for weight loss. The source indicates the representative is a former sales rep, but no specific date of the lawsuit filing is provided in the evidence.

Limitations

The source provides no specific date for the lawsuit filing, only the publication date of the article. It does not specify the exact location of the luncheon where the alleged off-label promotion occurred, nor does it confirm the exact date of the termination.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 11/11/2026, 01:50:45 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeih73duk4tnjdrw4hmqk7p2v5bmq5nvhcclxc5bvga4byjw42xpptm